All
Griseofulvin should remain standard in tinea capitis
January 1st 2002Munich - Newer oral antifungals have efficacy similar to griseofulvin in tinea capitis, possibly with a shorter duration of therapy. But for now, the old and familiar standby should remain the treatment of choice, according to Peter Mayser, M.D., senior physician, Justus Liebig University, Giessen, Germany.
TNF blockers control psoriatic arthritis
January 1st 2002San Francisco - Both tumor necrosis factor (TNF) blockers etanercept and infliximab continue to play an emerging role in the treatment of psoriatic arthritis (PsA), according to two new studies presented at the American College of Rheumatology annual meeting here.
Wound Assessment most Vital in Achieving Favorable Outcome
December 1st 2001Dallas - Knowing the different types of wound dressings available and their indications is important, but being able to assess wounds and determine whether the healing is proceeding well is an even more critical skill, Gregg M. Menaker, M.D., said at the annual joint meeting of the American Society of Dermatologic Surgery/American College of Mohs Micrographic Surgery and Oncology.
Interest in Restoring Volume Stimulus for New Fillers
December 1st 2001DALLAS - The list of fillers for facial volume augmentation is long and growing, but in choosing among the many options, the most important thing for users to keep in mind, said Arnold W. Klein, M.D., is: "It's not what you use, but how you use it."
Guidelines Ensure Safety of Special Needs Patients
December 1st 2001DALLAS - Guideline development can optimize management of dermatologic surgery patients with special needs, Clark C. Otley, M.D., said at the annual joint meeting of the American Society for Dermatologic Surgery and the American College of Mohs Micrographic Surgery and Cutaneous Oncology.
No Benefit to Low-Grade Lymphoma Subgroups
December 1st 2001MUNICH - While primary cutaneous B-cell lymphomas must be clearly separated from non-Hodgkin's B-cell lymphomas with secondary cutaneous involvement and from cutaneous B-cell pseudolymphomas, "from the truly clinical and prognostic point of view, low-grade lymphomas are one disease," according to Nicola Pimpinelli, M.D., at the annual meeting of the European Academy of Dermatology and Venereology.
Theory of Genetic Mosaicism Evolves
December 1st 2001MUNICH - Dermatologists now have a clinical case that supports the loss of heterozygosity theory for rare Type 2 form of segmental types of autosomal dominant (AD) skin disorders, Peter Itin, M.D., said at the annual meeting of the European Academy of Dermatology and Venereology.
Wound assessment most vital in achieving favorable outcome
December 1st 2001DALLAS - Knowing the different types of wound dressings available and their indications is important, but being able to assess wounds and determine whether the healing is proceeding well is an even more critical skill, Gregg M. Menaker, M.D., said at the annual joint meeting of the American Society of Dermatologic Surgery/American College of Mohs Micrographic Surgery and Oncology.
Ciprofloxacin study warns of adverse events
November 1st 2001Ciprofloxacin (Cipro), the medicine of choice for treatingcutaneous anthrax as well as other forms of the disease, can cause adversedrug reactions in both the central nervous system and the peripheral nervoussystem, according to studies in The Journal of Pharmacotherapy